Subscribe to Updates

    Get the latest health news from HerCancer about cancer & its various facts and treatments .

    What's Hot

    Oklahoma scientists develop promising cancer drug

    June 16, 2022

    Camp Kemo provides community for kids dealing with cancer

    June 16, 2022

    OU OK-1 cancer treatment drug heads to clinical trial

    June 15, 2022
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Her CancerHer Cancer
    Subscribe
    • Home
    • Women’s Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
    • Gynecologic Cancers
    Her CancerHer Cancer
    Home»Breast Cancer»EpiAxis Therapeutics Announces Positive Clinical Trial Data for its New Drug Program to Inhibit Metastatic Breast Cancer
    Breast Cancer

    EpiAxis Therapeutics Announces Positive Clinical Trial Data for its New Drug Program to Inhibit Metastatic Breast Cancer

    adminBy adminJune 9, 2022No Comments4 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    EpiAxis Therapeutics is based in Sydney, Australia.

    EpiAxis Therapeutics has announced a pioneering clinical study, showing that an epigenetic inhibitor combined with chemotherapy can treat metastatic cancer.

    Results of this exciting new study provide proof of concept for our drug development program for a first in class therapy to inhibit nuclear LSD1 and potentially modulate metastatic breast cancer.”

    — Dr. Jeremy Chrisp

    SYDNEY, AUSTRALIA, June 9, 2022 /EINPresswire.com/ — EpiAxis Therapeutics has announced the results of its pioneering clinical trial EPI-PRIMED, the first time that an epigenetic inhibitor was used in combination with chemotherapy to treat metastatic cancer.

    The purpose of the EPI-PRIMED study was to investigate the safety of the combination, nab-paclitaxel and an irreversible LSD1 inhibitor, in patients with metastatic breast cancer (mBC).

    Women with inoperable or metastatic breast cancer from three Australian facilities: Canberra Region Cancer Centre, Southern Medical Day Care Centre and Liverpool Hospital participated in the study. The results of this trial have now been published in leading cancer journal Frontiers of Oncology.

    CEO Jeremy Chrisp said the results of the study provide proof of concept for the company’s current drug development program for its first in class therapies to inhibit nuclear LSD1. In particular EpiAxis was pleased to note the biomarker results indicate that inhibition of LSD1 was associated with phenotypic change away from an aggressive phenotype in cancer cells.

    “The publication of this study is the culmination of several years’ work and the results are important for both patients and the company, as we have demonstrated that nuclear inhibition of LSD1 is possible and results in cell reprogramming,” Dr Chrisp said.

    “This indicates that we are on the right track to progress our novel first in class candidates to a new clinical trial. We would like to thank the staff and patients of the three sites that participated, as well as EpiAxis Therapeutics founding scientist Professor Sudha Rao. We look forward to sharing the immune data from the study in the near future.”

    The findings of the EPI-PRIMED study give EpiAxis a solid foundation for its next clinical trial using its novel peptide inhibitors. The company is currently working with The Sage Group to raise US$12million to advance a candidate into an IND enabled program.

    Dr Chrisp will be attending the BIO International Convention with The Sage Group from 13-16 June 2022 at San Diego Convention Center to facilitate discussions with interested parties.

    The full EPI-PRIMED publication can be found here:

    https://www.frontiersin.org/articles/10.3389/fonc.2022.862427/full

    For more information about EpiAxis Therapeutics and partnering opportunities for its pipeline drug candidates, please contact:

    Dr Jeremy Chrisp

    Phone: +61 421 012 268

    j.chrisp@epiaxistherapeutics.com

    Dr Bill Mason

    The Sage Group

    The Stockyard

    Creake Road, Syderstone, UK PE31 8SG

    Tel: +44 (0) 7785 950134

    wtm@sagehealthcare.com

    Or

    Wayne Pambianchi

    The Sage Group Inc.

    1802 Route 31 North

    #381 Clinton

    New Jersey 08809 USA

    Phone: +1 908 2306170

    wpambianchi@sagehealthcare.com

    ABOUT EPIAXIS THERAPEUTICS:

    EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather

    than a fatal one, by using epigenetic science to create a completely different approach to cancer

    treatment. Our therapies work differently to existing – and often toxic – treatments by

    reprogramming the cancer cells back towards normal cells.

    ABOUT THE SAGE GROUP

    The Sage Group is a leader in the provision of strategic and transactional advice to healthcare

    companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields.

    Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The

    Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous

    transactions including divestitures, alliances, acquisitions and financings with values ranging from $5

    million to $500 million.

    Dr. Bill Mason
    The Sage Group
    +44 7785 950134
    email us here

    You just read:

    News Provided By

    June 09, 2022, 06:00 GMT

    Distribution channels:
    Banking, Finance & Investment Industry, Business & Economy, Companies, Healthcare & Pharmaceuticals Industry, Media, Advertising & PR, Science, Social Media, Sports, Fitness & Recreation, Technology, World & Regional
    …


    EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
    As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
    tries to define some of the boundaries that are reasonable in today’s world. Please see our
    Editorial Guidelines
    for more information.

    Submit your press release

    Announces breast cancer Clinical Data drug EpiAxis for Inhibit its Metastatic New Positive Program Therapeutics to Trial
    admin
    • Website

    Related Posts

    Liquid Biopsies and Future of Cancer Treatment

    June 15, 2022

    Biden May Stop His Cancer Moonshot’s Launch

    June 15, 2022

    Breast Cancer Society of Canada Grants $250,000 To

    June 15, 2022

    Leave A Reply Cancel Reply

    Don't Miss
    Ovarian Cancer

    Oklahoma scientists develop promising cancer drug

    By adminJune 16, 20220

    Dena Newlun, a patient at OU Health Stephenson Cancer Center, talks about the importance of…

    Camp Kemo provides community for kids dealing with cancer

    June 16, 2022

    OU OK-1 cancer treatment drug heads to clinical trial

    June 15, 2022

    Megyn Kelly Torches Fox News Over Segment Celebrating Child Mutilation

    June 15, 2022
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    Our Picks

    Oklahoma scientists develop promising cancer drug

    June 16, 2022

    Camp Kemo provides community for kids dealing with cancer

    June 16, 2022

    OU OK-1 cancer treatment drug heads to clinical trial

    June 15, 2022

    Megyn Kelly Torches Fox News Over Segment Celebrating Child Mutilation

    June 15, 2022

    Subscribe to Updates

    Get the latest health news from HerCancer about cancer & its various facts and treatments .

    Facebook Twitter Instagram
    • About Us
    • Contact Us
    • Privacy Policy
    • Terms
    © 2022 . Designed by HerCancer.

    Type above and press Enter to search. Press Esc to cancel.